LAM
ARIA

Lebenthal Asset Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Lebenthal Asset Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,710
Closed -$23K – 819
2016
Q3 		$23K Buy
+1,710
New +$17.2K ﹤0.01% 581

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Lebenthal Asset Management's ARIA Position: Q4 2016 in Review

Lebenthal Asset Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2016, closing a stake of 1,710 shares — an estimated $23K sold.

Lebenthal Asset Management first reported a position in ARIA in Q3 2016 and held it in 1 quarter. The position peaked at $23K in Q3 2016. 200 funds tracked by Wall St. Rank hold ARIA as of Q4 2016.

  • Lebenthal Asset Management reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Lebenthal Asset Management sold 1,710 Ariad Pharmaceuticals Inc shares in Q4 2016, an estimated $23K.
  • Lebenthal Asset Management first reported a position in Ariad Pharmaceuticals Inc in Q3 2016 and held it in 1 quarter.
  • Lebenthal Asset Management's Ariad Pharmaceuticals Inc position peaked at $23K in Q3 2016.
  • 200 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2016.

Based on Lebenthal Asset Management's 13F filing for Q4 2016, filed 15 Feb 2017.